In contrast to suppressors known to be prone to mutation, i.e., p53 and PTEN, to our knowledge, CYTL1 harbors rare loss-of-function variants.17,31 These features of CYTL1 as a novel tumor suppressor may be very important not only for our understanding of tumor suppressors but also for the development of new antitumor approaches. The gene discussed is TP53; the disease is neoplasm.